CoChat

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

Harrison, Stephen A., Bashir, Mustafa R., Lee, Kyoung-Jin, Shim-Lopez, Jennifer, Lee, Jonathan, Wagner, Brandee, Smith, Nicholas D., Chen, Hubert C., Lawitz, Eric J. · 2021 · Journal of Hepatology
Cited by 130

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Farnesoid X receptor (FXR) agonists have been validated to benefit patients with nonalcoholic steatohepatitis (NASH), although improvements in efficacy and/or tolerability remain elusive. METHODS In this 12-week, randomized, placebo (PBO)-controlled study, we evaluated MET409 - a non-bile acid agonist with a unique chemical scaffold - in three cohorts of subjects with NASH: 80 mg (n=20), 50 mg (n=19), and PBO (n=19). RESULTS At Week 12, MET409 lowered liver fat content (LFC), with mean relative reductions of 55% (80 mg) and 38% (50 mg) vs 6% in PBO (P<0.001). MET409 achieved ≥30% relative LFC reduction in 93% (80 mg) and 75% (50 mg) of subjects vs 11% in PBO (P<0.001) and normalized LFC (≤5%) in 29% (80 mg) and 31% (50 mg) of subjects vs 0% in PBO (P<0.05). An increase in alanine aminotransferase (ALT) was observed with MET409, confounding Week 12 changes from baseline (-25% for 80 mg, 28% for 50 mg). Nonetheless, MET409 achieved ≥30% relative ALT reduction in 50% (80 mg) and 31% (50 mg) of subjects vs 17% in PBO. MET409 was associated with on-target high-density lipoprotein cholesterol decreases (mean changes of -23.4% for 80 mg and -20.3% for 50 mg vs 2.6% in PBO) and low-density lipoprotein cholesterol (LDL-C) increases (mean changes of 23.7% for 80 mg and 6.8% for 50 mg vs -1.5% in PBO). Pruritus (mild-moderate) occurred in 16% (50 mg) and 40% (80 mg) of MET409-treated subjects. CONCLUSION MET409 lowered LFC in 12 weeks in NASH patients and delivered a differentiated pruritus and LDL-C profile at 50 mg, providing the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.01.047

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 130

Metadata

Authors
Harrison, S. A., Bashir, M. R., Lee, K.-J., Shim-Lopez, J., Lee, J., Wagner, B., Smith, N. D., Chen, H. C., & Lawitz, E. J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2021-07
Volume
75
Issue
1
Pages
25-33
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3128716033
Cited by
130
References
4
FWCI
14.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2021.01.047
The paper
Harrison, S. A., Bashir, M. R., Lee, K.-J., Shim-Lopez, J., Lee, J., Wagner, B., Smith, N. D., Chen, H. C., & Lawitz, E. J. (2021). A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.01.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.